Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc.

Biotechnology • Healthcare • Montreal, QC, United States • MIST (NMS)

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

514 336 0444 1111 Dr. Frederik-Philips Boulevard, Montreal, QC H4M 2X6, Canada

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance
Yahoo Finance • Dec 16
Milestone Pharmaceuticals (MIST) Price Target Increased by 76.00% to 6.73 - Nasdaq
Nasdaq • Dec 21
Milestone Pharmaceuticals’ Stock Surges as Cardamyst Receives FDA Approval​ - StocksToTrade
StocksToTrade • Dec 24
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
Stock Titan • Jan 6
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen - MarketBeat
MarketBeat • Dec 21

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Milestone Pharmaceuticals Inc. had layoffs?
No layoff events have been recorded for Milestone Pharmaceuticals Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Milestone Pharmaceuticals Inc. have?
Milestone Pharmaceuticals Inc. has approximately 33 employees.
What industry is Milestone Pharmaceuticals Inc. in?
Milestone Pharmaceuticals Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Milestone Pharmaceuticals Inc. a publicly traded company?
Yes, Milestone Pharmaceuticals Inc. is publicly traded under the ticker symbol MIST on the NMS. The company has a market capitalization of approximately $0.17 billion.
Where is Milestone Pharmaceuticals Inc. headquartered?
Milestone Pharmaceuticals Inc. is headquartered in Montreal, QC, United States at 1111 Dr. Frederik-Philips Boulevard, Montreal, QC H4M 2X6, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.